Fibrillin-1 (FBN1) gene frameshift mutations in Marfan patients:: genotype-phenotype correlation

被引:29
作者
Pepe, G
Giusti, B
Evangelisti, L
Porciani, MC
Brunelli, T
Giurlani, L
Attanasio, M
Fattori, R
Bagni, C
Comeglio, P
Abbate, R
Gensini, GF
机构
[1] Univ Florence, Dipartimento Area Crit Med Chirurg, Sez Clin Med Gen & Clin Specialistiche, I-50134 Florence, Italy
[2] Univ Roma Tor Vergata, Dipartimento Biol, I-00173 Rome, Italy
[3] Univ Roma Tor Vergata, Dipartimento Med Interna, I-00173 Rome, Italy
[4] Univ Bologna, Dipartimento Radiol, Unita Cardiovasc, Bologna, Italy
关键词
aortic aneurysm; fibrillin-1; gene; frameshift mutations; Marfan syndrome; MASS;
D O I
10.1034/j.1399-0004.2001.590610.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Marfan syndrome (MFS) is a multisystemic disease associated with mutations in the fibrillin-1 gene. Most of the reported mutations are missense substitutions mainly affecting the epidermal growth factor (EGF)-like protein domain structure and the calcium-binding (cb) site. The aim of our study was to investigate the correlation between fibrillin-1 frameshift mutations and the clinical phenotype in patients affected by MFS. In 48 out of 66 Marfan patients a pathogenetic mutation was found. We detected novel mutations causing premature termination codon in exons 19, 37, 40 and 41 of four Italian patients. The first mutation in exon 19 (cbEGF #8 domain) results in a clinical phenotype involving mainly the skeletal and cardiovascular systems. Interestingly, we noticed that, while mutations in exons 37 and 41 (eight cysteine domains #4 and #5) are milder, the mutation in exon 40 (cbEGF #24 domain) is more severe and causes major cardiovascular involvement with thoracic and abdominal aortic aneurysms. It is noteworthy that the degree of the severity in the phenotype of one of our patients and another from the literature carrying a mutation in exon 41 could be explained with alterations in mRNA expression.
引用
收藏
页码:444 / 450
页数:7
相关论文
共 32 条
[1]   DETERMINATION OF FREE AND TOTAL HOMOCYSTEINE IN HUMAN-PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION [J].
ARAKI, A ;
SAKO, Y .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 422 :43-52
[2]  
Attanasio M, 1998, THROMB HAEMOSTASIS, V79, P959
[3]   Marfan Database (third edition):: new mutations and new routines for the software [J].
Collod-Béroud, G ;
Béroud, C ;
Ades, L ;
Black, C ;
Boxer, M ;
Brocks, DJH ;
Holman, KJ ;
de Paepe, A ;
Francke, U ;
Grau, U ;
Hayward, C ;
Klein, HG ;
Liu, WG ;
Nuytinck, L ;
Peltonen, L ;
Perez, ABA ;
Rantamäki, T ;
Junien, C ;
Boileau, C .
NUCLEIC ACIDS RESEARCH, 1998, 26 (01) :229-233
[4]  
COOPER DN, 1991, HUM GENET, V87, P409
[5]  
DEBAKEY ME, 1982, SURGERY, V92, P1118
[6]  
DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO
[7]  
2-R
[8]  
Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504
[9]   MUTATIONS IN THE HUMAN GENE FOR FIBRILLIN-1 (FBN1) IN THE MARFAN-SYNDROME AND RELATED DISORDERS [J].
DIETZ, HC ;
PYERITZ, RE .
HUMAN MOLECULAR GENETICS, 1995, 4 :1799-1809
[10]   4 NOVEL FBN1 MUTATIONS - SIGNIFICANCE FOR MUTANT TRANSCRIPT LEVEL AND EGF-LIKE DOMAIN CALCIUM-BINDING IN THE PATHOGENESIS OF MARFAN-SYNDROME [J].
DIETZ, HC ;
MCINTOSH, I ;
SAKAI, LY ;
CORSON, GM ;
CHALBERG, SC ;
PYERITZ, RE ;
FRANCOMANO, CA .
GENOMICS, 1993, 17 (02) :468-475